AX-2911
/ ProQR
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 13, 2025
ProQR Announces Year End 2024 Operating and Financial Results
(GlobeNewswire)
- "Anticipated Upcoming Events...AX-2911 targeting PNPLA3 for MASH: 2025 clinical candidate selection; 2026 clinical trial initiation and topline data readout."
Clinical data • New trial • Pipeline update • Metabolic Dysfunction-Associated Steatohepatitis
1 to 1
Of
1
Go to page
1